Somatostatin receptor-targeted DOTATATE PET/CT in breast cancer and breast lesions: a systematic review of detection, incidental findings and theranostic potential

Abstract Background Somatostatin receptor 2 (SSTR2) is expressed by a subset of breast cancers, particularly oestrogen receptor (ER)-positive tumours. DOTATATE PET/CT, the reference standard for neuroendocrine tumour (NET) imaging, is increasingly relevant to breast cancer staging, incidental findings and theranostic selection. We systematically reviewed its clinical performance. Methods Following PRISMA 2020 (PROSPERO CRD420261508548), Embase, Scopus and PubMed were searched to 16 September 2026, supplemented by citation searching. Studies reporting DOTATATE PET findings in breast cancer or breast lesions were included. Risk of bias was assessed with QUADAS-2 and Joanna Briggs Institute tools, certainty with GRADE, and findings were synthesised narratively. Results Nineteen studies (four prospective, two retrospective cohorts, three case series, ten case reports) including 107 patients with breast carcinoma were analysed. In head-to-head comparisons (n = 56), DOTATATE detected disease in most patients and matched 18 F-FDG for skeletal (252 vs 255 lesions) and nodal metastases, but identified half as many visceral metastases (134 vs 262), particularly in the liver. Uptake favoured ER-positive, lobular and neuroendocrine tumours. Focal breast uptake occurred on 1.1% of scans performed for other indications; 21.4% of characterised lesions were malignant and SUVmax did not discriminate benign from malignant lesions. Krenning scores ≥ 3 were found in 15/76 (19.7%) patients across three prospective studies. Certainty of evidence was very low. Conclusions DOTATATE PET/CT complements, but cannot replace, 18 F-FDG for breast cancer staging, and is less established than 18 F-FES. Incidental breast uptake warrants standard breast work-up regardless of intensity. Around one-fifth of patients with ER-positive metastatic disease show high SSTR expression, although whether this has therapeutic relevance remains uncertain.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11425000/v1
Primary Topic
Medical Imaging Techniques and Applications
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Somatostatin receptor-targeted DOTATATE PET/CT in breast cancer and breast lesions: a systematic review of detection, incidental findings and theranostic potential

Samantha Chen, Hugo C. Temperley, Zi Qin Ng, Cormac B. Mulhall et al.
4 links
Research Square
Medical Imaging Techniques and Applications
preprint

Somatostatin receptor-targeted DOTATATE PET/CT in breast cancer and breast lesions: a systematic review of detection, incidental findings and theranostic potential

Samantha Chen, Hugo C. Temperley, Zi Qin Ng, Cormac B. Mulhall, Daragh Slattery, Elliot Foy
preprint en

Abstract

Abstract Background Somatostatin receptor 2 (SSTR2) is expressed by a subset of breast cancers, particularly oestrogen receptor (ER)-positive tumours. DOTATATE PET/CT, the reference standard for neuroendocrine tumour (NET) imaging, is increasingly relevant to breast cancer staging, incidental findings and theranostic selection. We systematically reviewed its clinical performance. Methods Following PRISMA 2020 (PROSPERO CRD420261508548), Embase, Scopus and PubMed were searched to 16 September 2026, supplemented by citation searching. Studies reporting DOTATATE PET findings in breast cancer or breast lesions were included. Risk of bias was assessed with QUADAS-2 and Joanna Briggs Institute tools, certainty with GRADE, and findings were synthesised narratively. Results Nineteen studies (four prospective, two retrospective cohorts, three case series, ten case reports) including 107 patients with breast carcinoma were analysed. In head-to-head comparisons (n = 56), DOTATATE detected disease in most patients and matched 18 F-FDG for skeletal (252 vs 255 lesions) and nodal metastases, but identified half as many visceral metastases (134 vs 262), particularly in the liver. Uptake favoured ER-positive, lobular and neuroendocrine tumours. Focal breast uptake occurred on 1.1% of scans performed for other indications; 21.4% of characterised lesions were malignant and SUVmax did not discriminate benign from malignant lesions. Krenning scores ≥ 3 were found in 15/76 (19.7%) patients across three prospective studies. Certainty of evidence was very low. Conclusions DOTATATE PET/CT complements, but cannot replace, 18 F-FDG for breast cancer staging, and is less established than 18 F-FES. Incidental breast uptake warrants standard breast work-up regardless of intensity. Around one-fifth of patients with ER-positive metastatic disease show high SSTR expression, although whether this has therapeutic relevance remains uncertain.

Research Square
The University of Western Australia (AU), Royal Perth Hospital (AU), Sir Charles Gairdner Hospital (AU), Saint James Hospital Group (MT)
Good health and well-being
Medical Imaging Techniques and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon